3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Hodgkin Disease
37
Melanoma
22
Lymphoma
8
Sarcoma
6
Neoplasm Metastasis
5
Leiomyosarcoma
3
Uveal Melanoma
2
Skin Neoplasms
2
Sarcoma, Synovial
2
Neoplasms
2
Thyroid Neoplasms
1
Solitary Fibrous Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Immunotherapy
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Hemangioendothelioma
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Interventions
Diathermy
20
Radiotherapy
11
Fluorouracil
4
Drug Therapy
4
Cisplatin
4
Radiation
3
Immune Checkpoint Inhibitors
3
Brachytherapy
3
tislelizumab
2
Surgical Procedures, Operative
2
Solutions
2
Immunotherapy
2
Hyperthermia, Induced
2
Hydrogen Peroxide
2
Conization
2
Capecitabine
2
spartalizumab
1
anlotinib
1
Temozolomide
1
Saline Solution
1
Radiation Dose Hypofractionation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Ifosfamide
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
Folfox protocol
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hyperthermia
×
Dacarbazine
×
Clear all
NCT06835049
2025-12-30
TNT-HYPE
Swiss Cancer Institute
Phase 2
Recruiting
24 enrolled